Fighting Parkinson’s

Development of a patient-specific stem cell therapy for the treatment of Parkinson’s disease

Harvard University
Cambridge, MA Dr. Penny Hallett
Dr. Ole Isacson

The National Stem Cell Foundation (NSCF) and The Michael J. Fox Foundation (MJFF) are partnering to fund the pre-clinical development of a therapy to replace the dopamine-producing neurons that are lost in Parkinson’s disease, the second most common brain disease after Alzheimer’s. The partnership supports the translational work of Dr. Penny Hallett, Director of the Neuroregeneration Institute at Harvard Medical School/McLean Hospital and Dr. Ole Isacson, founding Director of the Neuroregeneration Institute and principal faculty of the Harvard Stem Cell Institute. Engineering skin stem cells to become patient-specific dopamine-producing neurons, the goal is to implant the neurons developed from a patient’s own skin cells to alleviate or prevent Parkinson’s motor symptoms of tremor, rigidity and slowness.